Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance

June, 2018, Chimeric Antigen Receptor Therapy, N. Engl. J. Med., 379, 64, 10.1056/NEJMra1706169

Wang, 2017, Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment, Protein Cell, 8, 896, 10.1007/s13238-017-0400-z

Han, 2017, Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors, Cancer Lett., 390, 188, 10.1016/j.canlet.2016.12.037

Yeku, 2017, Adoptive T-Cell Therapy for Solid Tumors, Am. Soc. Clin. Oncol. Educ. Book, 37, 193, 10.1200/EDBK_180328

Arabi, 2018, Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials, Exp. Cell Res., 369, 1, 10.1016/j.yexcr.2018.05.009

Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: Clinical evaluation and management of on-target toxicity, Mol. Ther., 21, 904, 10.1038/mt.2013.17

Wilson, 1983, Immunochemical characterization of a human high molecular weight--melanoma associated antigen identified with monoclonal antibodies, Cancer Immunol. Immunother., 14, 196, 10.1007/BF00205360

Ilieva, 2017, Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types, Front. Immunol., 8, 1911, 10.3389/fimmu.2017.01911

Natali, 1983, Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens, J. Cutan. Pathol., 10, 225, 10.1111/j.1600-0560.1983.tb01489.x

Li, 2003, Human uveal melanoma expresses NG2 immunoreactivity, Br. J. Ophthalmol., 87, 629, 10.1136/bjo.87.5.629

Li, 2005, In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells, Invest. Ophthalmol. Vis. Sci., 46, 4365, 10.1167/iovs.05-0559

Chekenya, 1999, The NG2 chondroitin sulfate proteoglycan: Role in malignant progression of human brain tumours, Int. J. Dev. Neurosci., 17, 421, 10.1016/S0736-5748(99)00019-2

Godal, 1986, Unexpected expression of the 250 kD melanoma-associated antigen in human sarcoma cells, Br. J. Cancer, 53, 839, 10.1038/bjc.1986.142

Shoshan, 1999, Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors, Proc. Natl. Acad. Sci. USA, 96, 10361, 10.1073/pnas.96.18.10361

Yadavilli, 2016, The Role of NG2 Proteoglycan in Glioma, Transl. Oncol., 9, 57, 10.1016/j.tranon.2015.12.005

Behm, 1996, Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements, Blood, 87, 1134, 10.1182/blood.V87.3.1134.bloodjournal8731134

Hilden, 1997, MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia, Blood, 89, 3801, 10.1182/blood.V89.10.3801

Schwartz, 2003, Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: Close association with MLL rearrangement and a CD10(-)/CD24(-)/CD65s(+)/CD15(+) B-cell phenotype, Leukemia, 17, 1589, 10.1038/sj.leu.2402989

Smith, 1996, The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23, Blood, 87, 1123, 10.1182/blood.V87.3.1123.bloodjournal8731123

Wuchter, 2000, Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1, Leukemia, 14, 1232, 10.1038/sj.leu.2401840

Wang, 2010, CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer, J. Natl. Cancer Inst., 102, 1496, 10.1093/jnci/djq343

Nicolosi, 2015, Theranostic impact of NG2/CSPG4 proteoglycan in cancer, Theranostics, 5, 530, 10.7150/thno.10824

Ferrone, 1993, Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma, Pharm. Ther., 57, 259, 10.1016/0163-7258(93)90058-L

Schlingemann, 1990, Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds, Am. J. Pathol., 136, 1393

Midwood, 1998, Expression of NG2/human melanoma proteoglycan in human adult articular chondrocytes, Osteoarthr. Cartil., 6, 297, 10.1053/joca.1998.0128

Tordsson, 2000, Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma, Cancer Immunol. Immunother., 48, 691, 10.1007/s002620050018

Smyth, 2018, Markers for human brain pericytes and smooth muscle cells, J. Chem. Neuroanat., 92, 48, 10.1016/j.jchemneu.2018.06.001

Petrini, 2003, Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies, Mol. Cell. Neurosci., 23, 219, 10.1016/S1044-7431(03)00033-2

Challier, 2001, Characterization of first trimester human fetal placental vessels using immunocytochemical markers, Cell. Mol. Biol (Noisy-Le-Grand), 47 Online Pub, OL79

Campoli, 2004, Human high molecular weight-melanoma-associated antigen (HMW-MAA): A melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance, Crit. Rev. Immunol., 24, 267, 10.1615/CritRevImmunol.v24.i4.40

Wang, 2015, Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors, Expert Opin. Ther. Targets, 19, 1339, 10.1517/14728222.2015.1068759

Keizer, 1986, Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells, Int. J. Cancer, 38, 465, 10.1002/ijc.2910380403

Ozerdem, 2006, Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer, Prostate, 66, 294, 10.1002/pros.20346

Ozerdem, 2006, Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in nerve/glial antigen 2 proteoglycan knockout mouse, Ophthalmic. Res., 38, 251, 10.1159/000094833

Ampofo, 2017, The regulatory mechanisms of NG2/CSPG4 expression, Cell. Mol. Biol. Lett., 22, 4, 10.1186/s11658-017-0035-3

Schroff, 1985, Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen, J. Natl. Cancer Inst., 74, 299

Allen, 2005, Intralesional targeted alpha therapy for metastatic melanoma, Cancer Biol. Ther., 4, 1318, 10.4161/cbt.4.12.2251

Brehm, 2014, A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues, Cancer Lett., 352, 228, 10.1016/j.canlet.2014.07.006

Hjortland, 2004, Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme, J. Neurosurg., 100, 320, 10.3171/jns.2004.100.2.0320

Schwenkert, 2008, A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells, Melanoma Res., 18, 73, 10.1097/CMR.0b013e3282f7c8f9

Jordaan, S., Chetty, S., Mungra, N., Koopmans, I., van Bommel, P.E., Helfrich, W., and Barth, S. (2017). CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. Biomedicines, 5.

Rybczynska, 2010, Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo, Mol. Cancer, 9, 301, 10.1186/1476-4598-9-301

Beard, 2014, Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells, J. Immunother. Cancer, 2, 25, 10.1186/2051-1426-2-25

Geldres, 2014, T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo, Clin. Cancer Res., 20, 962, 10.1158/1078-0432.CCR-13-2218

Abken, 2001, A novel strategy in the elimination of disseminated melanoma cells: Chimeric receptors endow T cells with tumor specificity, Recent Results Cancer Res., 158, 249, 10.1007/978-3-642-59537-0_25

Burns, 2010, A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas, Cancer Res., 70, 3027, 10.1158/0008-5472.CAN-09-2824

Losch, 2003, Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain, Int. J. Cancer, 103, 399, 10.1002/ijc.10826

Reinhold, 1999, Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor, J. Investig. Derm., 112, 744, 10.1046/j.1523-1747.1999.00586.x

Schmidt, 2011, Eradication of melanomas by targeted elimination of a minor subset of tumor cells, Proc. Natl. Acad. Sci. USA, 108, 2474, 10.1073/pnas.1009069108

Pellegatta, 2018, Constitutive and TNFalpha-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy, Sci. Transl. Med., 10, eaao2731, 10.1126/scitranslmed.aao2731

Harrer, D.C., Simon, B., Fujii, S.I., Shimizu, K., Uslu, U., Schuler, G., Gerer, K.F., Hoyer, S., Dorrie, J., and Schaft, N. (2017). RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an α/β T-cell receptor: A safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma. BMC Cancer, 17.

Krug, 2015, Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone, Cancer Immunol. Immunother., 64, 1623, 10.1007/s00262-015-1767-4

Dorrie, J., Babalija, L., Hoyer, S., Gerer, K.F., Schuler, G., Heinzerling, L., and Schaft, N. (2018). BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. Int. J. Mol. Sci., 19.

Krug, 2014, A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor, Cancer Immunol. Immunother., 63, 999, 10.1007/s00262-014-1572-5

Reddy, 2004, Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: An in vitro model to monitor cellular immune function, J. Immunol. Methods, 293, 127, 10.1016/j.jim.2004.07.006

Barrett, 2014, Chimeric antigen receptor therapy for cancer, Annu. Rev. Med., 65, 333, 10.1146/annurev-med-060512-150254

Kalos, 2013, Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, 39, 49, 10.1016/j.immuni.2013.07.002

Dai, 2019, Standardizing CAR-T therapy: Getting it scaled up, Biotechnol. Adv., 37, 239, 10.1016/j.biotechadv.2018.12.002

Wang, 2016, Clinical manufacturing of CAR T cells: Foundation of a promising therapy, Mol. Ther. Oncolytics, 3, 16015, 10.1038/mto.2016.15

Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience, J. Clin. Oncol., 24, e20, 10.1200/JCO.2006.05.9964

Zhao, 2005, Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines, J. Immunol., 174, 4415, 10.4049/jimmunol.174.7.4415

Zhao, 2006, Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes, J. Immunother., 29, 398, 10.1097/01.cji.0000203082.20365.7f

Schaft, 2006, A new way to generate cytolytic tumor-specific T cells: Electroporation of RNA coding for a T cell receptor into T lymphocytes, Cancer Immunol. Immunother., 55, 1132, 10.1007/s00262-005-0098-2

Birkholz, 2009, Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer, Gene Ther., 16, 596, 10.1038/gt.2008.189

Tchou, 2017, Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer, Cancer Immunol. Res., 5, 1152, 10.1158/2326-6066.CIR-17-0189

Beatty, 2014, Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies, Cancer Immunol. Res., 2, 112, 10.1158/2326-6066.CIR-13-0170

Maus, 2013, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol. Res., 1, 26, 10.1158/2326-6066.CIR-13-0006

Beatty, 2018, Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial, Gastroenterology, 155, 29, 10.1053/j.gastro.2018.03.029

Svoboda, 2018, Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma, Blood, 132, 1022, 10.1182/blood-2018-03-837609

Noto, A., Ngauv, P., and Trautmann, L. (2013). Cell-based flow cytometry assay to measure cytotoxic activity. J. Vis. Exp., e51105.